Albinism clinical trials
The registry lists 17 studies for Albinism across 4 countries. 8 are recruiting or about to start. 9 of them are mainly about Albinism (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Albinism studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University Hospital, Bordeaux (3) · National Human Genome Research Institute (NHGRI) (3) · National Eye Institute (NEI) (3) · Maastricht University Medical Center (2) · Fondation Ophtalmologique Adolphe de Rothschild (1) · William Gahl, M.D. (1) · Queen's University, Belfast (1) · University of Minnesota (1)
What is being tested here
Drugs under test in Albinism studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Levodopa | 0 | 0 | 2 |
| Nitisinone | 0 | 0 | 1 |
| Pirfenidone | 0 | 0 | 1 |
| Carbidopa | 0 | 0 | 1 |
| Losartan | 0 | 0 | 1 |
| Zileuton | 0 | 0 | 1 |
| Acetylcysteine | 0 | 0 | 1 |
| Pravastatin | 0 | 0 | 1 |
| Erythromycin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Mar 2027FARD (RaDiCo Cohort) (RaDiCo-FARD) · Institut National de la Santé Et de la Recherche Médicale, France
Who these studies take
Of the 6 Albinism studies recruiting now, 3 (50%) set no upper age limit and 1 (17%) stop at 75 or younger. 6 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (100%) | 6 (100%) |
| 18 | 6 (100%) | 6 (100%) |
| 30 | 6 (100%) | 6 (100%) |
| 40 | 6 (100%) | 6 (100%) |
| 50 | 6 (100%) | 6 (100%) |
| 65 | 6 (100%) | 6 (100%) |
| 75 | 5 (83%) | 5 (83%) |
| 85 | 5 (83%) | 5 (83%) |
Across all 17 studies, recruiting or not: 24% stop at 75 or younger and 12% at 65; 71% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. search them.
- Clinical and Basic Investigations Into Hermansky-Pudlak SyndromeRecruitingNCT000014561 country
- National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic DiseasesRecruitingNCT064916151 country
- Study of Chediak-Higashi SyndromeRecruitingNCT000059171 country
- FARD (RaDiCo Cohort) (RaDiCo-FARD)RecruitingNCT059544161 country
- Implementation of Long-read Sequencing for the Diagnosis of Rare Diseases.Not yet recruitingNCT074009131 country
- Reproductive Options in Inherited Skin DiseasesEnrolling by invitationNCT063303241 country
- Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive CounsellingRecruitingNCT063303501 country
- Functional Tests to Resolve Unsolved Rare Diseases. Rares.RecruitingNCT05696912Not applicable1 country
- Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced VisionCompletedNCT042817321 country
- Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General PopulationCompletedNCT04658381Not applicable1 country
- NGS Panel of Incomplete Forms of Ocular AlbinismCompletedNCT044952181 country
- Vision Response to Dopamine ReplacementTerminatedNCT01663935Phase 21 country
- Nitisinone for Type 1B Oculocutaneous AlbinismCompletedNCT01838655Phase 1/21 country
- Trial of L-DOPA as a Treatment to Improve Vision in AlbinismCompletedNCT01176435Phase 21 country
- Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak SyndromeCompletedNCT00001596Phase 21 country
- Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak SyndromeTerminatedNCT00467831Phase 1/21 country
- Visual Function and Ocular Pigmentation in AlbinismCompletedNCT000011531 country